OBJECTIVES: To evaluate the performance of a single determination of HIV viral load (VL) 6-12 months after starting antiretroviral therapy (ART) for identifying patients who will subsequently develop virological failure. METHODS: We selected HIV-infected patients with at least two VL determinations after 6 months of ART from an HIV cohort study in India. Patients were divided in two groups depending on whether the first VL was below (Group 1) or above (Group 2) 1000 copies/ml. Cut-off for virological failure was defined according to World Health Organization recommendation (>5000 copies/ml). RESULTS: The study included 584 patients and 560.1 person-years of follow-up. Of all virological failures, 83% were diagnosed at the first VL determination. The cumulative incidence of virological failure after 1 and 2 years since the first VL was 0.9% [95% confidence interval (CI), 0.3-2.7] and 1.7% (95% CI, 0.6-5), respectively, for Group 1, and 58.2% (95% CI, 47-69.7) and 63.1% (95% CI, 49.8-76.4), respectively, for Group 2. Compared with Group 1, patients from Group 2 had a hazard ratio for virological failure of 78.3 (95% CI, 27.8-220.2). CONCLUSIONS: A single VL determination after 6 months of ART was able to identify patients with high risk of virological failure.
OBJECTIVES: To evaluate the performance of a single determination of HIV viral load (VL) 6-12 months after starting antiretroviral therapy (ART) for identifying patients who will subsequently develop virological failure. METHODS: We selected HIV-infectedpatients with at least two VL determinations after 6 months of ART from an HIV cohort study in India. Patients were divided in two groups depending on whether the first VL was below (Group 1) or above (Group 2) 1000 copies/ml. Cut-off for virological failure was defined according to World Health Organization recommendation (>5000 copies/ml). RESULTS: The study included 584 patients and 560.1 person-years of follow-up. Of all virological failures, 83% were diagnosed at the first VL determination. The cumulative incidence of virological failure after 1 and 2 years since the first VL was 0.9% [95% confidence interval (CI), 0.3-2.7] and 1.7% (95% CI, 0.6-5), respectively, for Group 1, and 58.2% (95% CI, 47-69.7) and 63.1% (95% CI, 49.8-76.4), respectively, for Group 2. Compared with Group 1, patients from Group 2 had a hazard ratio for virological failure of 78.3 (95% CI, 27.8-220.2). CONCLUSIONS: A single VL determination after 6 months of ART was able to identify patients with high risk of virological failure.
Authors: Victor Ssempijja; Martha Nason; Gertrude Nakigozi; Anthony Ndyanabo; Ron Gray; Maria Wawer; Larry W Chang; Erin Gabriel; Thomas C Quinn; David Serwadda; Steven J Reynolds Journal: Clin Infect Dis Date: 2020-08-14 Impact factor: 9.079
Authors: April D Thames; Taylor P Kuhn; Zanjbeel Mahmood; Robert M Bilder; Timothy J Williamson; Elyse J Singer; Alyssa Arentoft Journal: Brain Imaging Behav Date: 2018-02 Impact factor: 3.978
Authors: Alexander Billioux; Gertrude Nakigozi; Kevin Newell; Larry W Chang; Thomas C Quinn; Ron H Gray; Anthony Ndyanabo; Ronald Galiwango; Valerian Kiggundu; David Serwadda; Steven J Reynolds Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Victor Ssempijja; Larry W Chang; Gertrude Nakigozi; Anthony Ndyanabo; Thomas C Quinn; Frank Cobelens; Maria Wawer; Ronald Gray; David Serwadda; Steven J Reynolds Journal: Open Forum Infect Dis Date: 2018-10-09 Impact factor: 3.835